Abstract
Cancer disease is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and around 8 million cancer-related deaths yearly. Estimates expect to increase these figures over the next few years. Therefore, it is very important to develop more effective and targeted therapies. Polysaccharides are widely used for biomedical and pharmaceutical applications due to their interesting properties, and can be utilised in the production of nanovehicles for drug delivery, since they frequently extend the half-life and improve the stability of chemotherapeutic agents in bloodstream allowing them to reach the tumour tissue. Moreover, polysaccharide-based nanovehicles are generally expected to increase the therapeutic benefit by reducing the undesired side effects and promoting a more efficient cellular uptake. Here, we highlight the application of various polysaccharides as nanovehicles in cancer therapy, focusing mainly on in vivo applications and describing the main advantages of each designed system in a critical way. The use of different polysaccharides interacting with metal nanoparticles to develop new nanovehicles for cancer therapy will also be discussed.
Keywords: Cancer therapy, drug delivery, EPR effect, in vivo therapy, non-viral vectors.
Current Pharmaceutical Design
Title:Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Volume: 21 Issue: 33
Author(s): Carlos Caro and David Pozo
Affiliation:
Keywords: Cancer therapy, drug delivery, EPR effect, in vivo therapy, non-viral vectors.
Abstract: Cancer disease is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and around 8 million cancer-related deaths yearly. Estimates expect to increase these figures over the next few years. Therefore, it is very important to develop more effective and targeted therapies. Polysaccharides are widely used for biomedical and pharmaceutical applications due to their interesting properties, and can be utilised in the production of nanovehicles for drug delivery, since they frequently extend the half-life and improve the stability of chemotherapeutic agents in bloodstream allowing them to reach the tumour tissue. Moreover, polysaccharide-based nanovehicles are generally expected to increase the therapeutic benefit by reducing the undesired side effects and promoting a more efficient cellular uptake. Here, we highlight the application of various polysaccharides as nanovehicles in cancer therapy, focusing mainly on in vivo applications and describing the main advantages of each designed system in a critical way. The use of different polysaccharides interacting with metal nanoparticles to develop new nanovehicles for cancer therapy will also be discussed.
Export Options
About this article
Cite this article as:
Caro Carlos and Pozo David, Polysaccharide Colloids as Smart Vehicles in Cancer Therapy, Current Pharmaceutical Design 2015; 21 (33) . https://dx.doi.org/10.2174/1381612821666150820100812
DOI https://dx.doi.org/10.2174/1381612821666150820100812 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Editorial: Sulfur-Containing Amino Acids in Cardiovascular and Neural Physiology, Pathophysiology and Pharmacology: An Overview and Update
Current Medicinal Chemistry Development of Specific New ELISA for Bioanalysis of Cetuximab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Pharmaceutical Analysis Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography
Reviews on Recent Clinical Trials In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Current Pharmaceutical Design Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Phytochemical and Pharmacological Insight on Sesamol: An Updated Review
Current Bioactive Compounds γ-H2AX as a Therapeutic Target for Improving the Efficacy of Radiation Therapy
Current Cancer Drug Targets A Walk in Nature: Sesquiterpene Lactones as Multi-Target Agents Involved in Inflammatory Pathways
Current Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Herbal Folklore Medication for Liver Disorders
Current Traditional Medicine Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science